Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ablative Radiotherapy Clear all
Recruiting Phase 1Phase 2 Interventional

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

NCT07579195
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

NCT05470322
View directory record Official record
Conditions
Hidradenitis Suppurativa, Scarring
Interventions
Er: YAG laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Phase 2 Interventional

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

NCT04253483
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Ablative Radiotherapy
Radiation · Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Completed Not applicable Interventional Results available

Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

NCT04939246
View directory record Official record
Conditions
Metastatic Carcinoma
Interventions
Stereotactic ablative body radiation therapy
Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Miami, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars

NCT00735254
View directory record Official record
Conditions
Abdominoplasty Scars
Interventions
pulsed dye laser, Affirm Laser, combined PDL and Affirm Lasers, Placebo
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Phase 1 Interventional

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

NCT03824327
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00750269
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Phase 1 Interventional

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

NCT02353819
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Ablative Radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional

Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer

NCT04131634
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Stereotactic Ablative Radiation
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Not applicable Interventional

Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer

NCT05830838
View directory record Official record
Conditions
Malignant Prostate Neoplasm
Interventions
Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Recruiting Phase 3 Interventional

Total RadIoTherapy of Oligometastatic caNcerS

NCT06587490
View directory record Official record
Conditions
Oligometastatic Malignant Solid Neoplasm
Interventions
stereotactic ablative radiotherapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

NCT06260033
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer

NCT03892720
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT03361735
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Phase 2 Interventional

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

NCT05496959
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

NCT02781506
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab, SAbR
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Sep 26, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

NCT06103669
View directory record Official record
Conditions
Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma, Other Cancer
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT02599454
View directory record Official record
Conditions
Stage I Non-Small Cell Lung Cancer
Interventions
Atezolizumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Sacramento, California • Travis AFB, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

NCT04945642
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

NCT03541850
View directory record Official record
Conditions
PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 26, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

NCT07210086
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADT, ARSI, No ADT/ARSI -decline
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03522584
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Tremelimumab, Hypofractionated Image-Guided Radiation Therapy
Biological · Other · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 26, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

NCT04068649
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
Palliative Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Buffalo, New York • East Hills, New York • West Islip, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 26, 2026, 9:59 AM EDT
Suspended Phase 2 Interventional

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

NCT06014827
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 9:59 AM EDT